As such, there has been a growing emphasis on the development and validation of fluid biomarkers to aid in diagnosis of AD, including Aβ42, Aβ42/40, NfL, glial fibrillary acidic protein (GFAP), total tau (t-tau), and phosphorylated tau (p-tau).4–6. The gene discussed is MAPT; the disease is Alzheimer disease.